ACM
WGSWW

Altium Capital Management’s GeneDx Holdings Warrant WGSWW Stock Holding History

Altium Capital Management’s Portfolio WGSWW Stock Details WGSWW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-66,666
Closed -$345K – 156
2021
Q1 		$345K Buy
+66,666
New +$371K 0.1% 118

Other funds holding WGSWW

SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
AC
Athanor Capital New York $24.6M AUM 2.49% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Altium Capital Management's WGSWW Position: Q2 2021 in Review

Altium Capital Management sold out of GeneDx Holdings Warrant (WGSWW) in Q2 2021, closing a stake of 66,666 shares — an estimated $345K sold.

Altium Capital Management first reported a position in WGSWW in Q1 2021 and held it in 1 quarter. The position peaked at $345K in Q1 2021. 25 funds tracked by Wall St. Rank hold WGSWW as of Q2 2021.

  • Altium Capital Management reported no remaining GeneDx Holdings Warrant position as of Q2 2021 after selling out during the quarter.
  • Altium Capital Management sold 66,666 GeneDx Holdings Warrant shares in Q2 2021, an estimated $345K.
  • Altium Capital Management first reported a position in GeneDx Holdings Warrant in Q1 2021 and held it in 1 quarter.
  • Altium Capital Management's GeneDx Holdings Warrant position peaked at $345K in Q1 2021.
  • 25 funds tracked by Wall St. Rank held GeneDx Holdings Warrant as of Q2 2021.

Based on Altium Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.